Navigation Links
AcelRx Pharmaceuticals Reports Positive Results From a Phase 2 Clinical Trial of Sublingual Sufentanil NanoTabs(TM) in Treating Post-Operative Pain
Date:12/9/2008

cg or 15mcg of sufentanil. Doses were delivered sublingually as needed to treat pain with a 20-minute minimum re-dosing interval and patients were allowed to drop out of the study at any time. Positive results were also obtained for the primary endpoint following treatment with the 15mcg dose compared to placebo using two alternate methods for imputing missing data from drop-outs: baseline observation carried forward (BOCF), p = 0.007, and last observation carried forward (LOCF), p = 0.018. Importantly, there were no events of clinically significant respiratory depression for any dosing group. Based on these positive results, AcelRx intends to further advance clinical development of ARX-01 in 2009.

"We are pleased by the wonderful clinical results of our Phase 2 post-operative acute pain study," said Thomas A. Schreck, chairman and chief executive officer of AcelRx Pharmaceuticals. "This is the culmination of a great deal of hard work by a team of efficient, dedicated people over the last two years, and is therefore very gratifying indeed. This trial has the benefit of validating Sublingual Sufentanil NanoTabs as a robust product candidate for its initial in-hospital acute pain indication, as well as providing the foundation of safety and efficacy for the other programs in our pipeline."

About ARX-01 Sublingual Sufentanil NanoTabs

Sufentanil is currently approved as an intravenous (IV) anesthetic and is also indicated for epidural administration during labor and delivery. Due to their small size, ARX-01 Sublingual Sufentanil NanoTabs are convenient, well-tolerated, have high bioavailability and provide lower peak plasma levels compared to IV administration.

About the ARX-01 Oral Patient-Controlled Analgesia System

The ARX-01 Oral Patient-Controlled Analgesia (PCA) system is based on a proprietary pre-programmed, hand-held dispenser being developed by AcelRx. The AcelRx d
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar will ... and clinical safety assessment in biosimilars. , Regulatory frameworks ... biosimilar drug development, however the complex nature of biopharmaceuticals ... safety and efficacy extremely challenging. Based on the specific ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how ... latent viruses is the Epstein Barr Virus (EBV), and one ... is a chronic inflammatory disease that destroys the body’s joints. ... patients have high concentrations of EBV DNA in their bodies ...
(Date:1/15/2014)... 2014 AudioNotch is the internet's leading ... the treatment of tinnitus. Patients listen to sound therapy ... a period of weeks to months, their tinnitus volume decreases. ... forms: Notched Music and Notched White Noise. Now, AudioNotch is ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Histogen, Inc., ... products of cells grown under simulated embryonic conditions, today ... agreement with Suneva Medical, Inc. for physician-dispensed aesthetic products ... , This agreement is an amendment to the ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... Commence the Marketing ... Oncology Market, BASKING RIDGE, N.J., March 28 ... Inc. (MBTG) announced today that it has received an,$88,000 ... recently,announced distribution agreement with Ferring, Inc. of Canada. Ferring,Inc. ...
... TVM Capital Joins Investor Syndicate, VIENNA, ... company developing novel antibodies and antibody fragments,based ... today that it,has acquired future royalty obligations ... payment., Modular Antibody Technology was originally ...
... /PRNewswire/ -. Actavis Group, the,international generic pharmaceuticals ... separate approvals from the U.S. Food & ... (SR). Distribution,of the products will commence immediately., ... in,150mg strength, are the generic equivalent of ...
Cached Biology Technology:Ferring Initial Purchase Order and Guaranteed Letter of Credit Launches Five Year Contract 2Ferring Initial Purchase Order and Guaranteed Letter of Credit Launches Five Year Contract 3Antibody Engineering Company F-Star Buys Back Royalty Obligations 2Actavis Receives Approval of Generic Wellbutrin SR(R) and Zyban(R) Tablets in the U.S. 2
(Date:4/18/2014)... that sprout as soon as they,re planted may be good ... more careful. In the wild, a plant whose seeds sprouted ... disaster. More than just an insurance policy against late frosts ... has long-term advantages too: Plants whose seeds put off ... species, finds in a team of researchers working at the ...
(Date:4/17/2014)... , Respiratory syncytial virus (RSV) is a ... life-threating illness in very young and elderly populations. ... enters host cells through the fusion protein RSV ... interfering peptides that prevent bundle formation limit RSV ... susceptible to degradation. In this issue of the ...
(Date:4/17/2014)... Professor Marc Andr Gauthier and Professor Luca Razzari ... each been awarded large grants from the John ... for Innovation (CFI) for the acquisition of state-of-the-art ... be added matching grants from the Ministre de ... et de la Technologie (MESRST). These new laboratories ...
Breaking Biology News(10 mins):Plants with dormant seeds give rise to more species 2JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6New state-of-the-art biotech and nanotech equipment for INRS 2
... more than a dozen scientists from the U.S. Forest ... universities and Region 5 Ecology Program recently released a ... managers as they revise plans for the national forests ... The three most southern national forests in the Sierra ...
... new study from the University of Colorado Denver shows that ... some graves lavish and ornate while the vast majority were ... burials were so ornate, but what,s striking is that they ... 10,000 years," said Julien Riel-Salvatore, Ph.D., assistant professor of anthropology ...
... , , , , , , ... , , AUDIO: ... , Click here for more information. , ... , , , , ...
Cached Biology News:Science synthesis to help guide land management of nation's forests 2Early human burials varied widely but most were simple 2Early human burials varied widely but most were simple 3Low-pitched song indicates fairy-wren size 2Low-pitched song indicates fairy-wren size 3
Mouse polyclonal antibody raised against a partial recombinant CSRP3. NCBI Entrez Gene ID = 8048...
... [HDAC8-48] to HDAC8 Regulation of ... mechanisms such as DNA methylation, ATP-dependent ... of histones, which include the dynamic ... of lysine residues present in the ...
... 2-D Sample Preparation for Membrane Proteins ... process 25 membrane,protein extracts for 2-D gel ... Membrane Protein Extraction Kit , ... pellet,fractions with a packed cell weight of ...
...
Biology Products: